Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
RGEN's Cash to Debt is ranked higher than
84% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. RGEN: No Debt )
RGEN' s 10-Year Cash to Debt Range
Min: 3   Max: No Debt
Current: No Debt

Equity to Asset 0.91
RGEN's Equity to Asset is ranked higher than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. RGEN: 0.91 )
RGEN' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.98
Current: 0.91

0.5
0.98
Interest Coverage 457.46
RGEN's Interest Coverage is ranked higher than
59% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RGEN: 457.46 )
RGEN' s 10-Year Interest Coverage Range
Min: 194.44   Max: 9999.99
Current: 457.46

194.44
9999.99
F-Score: 6
Z-Score: 41.76
M-Score: -3.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 33.55
RGEN's Operating margin (%) is ranked higher than
96% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. RGEN: 33.55 )
RGEN' s 10-Year Operating margin (%) Range
Min: -312.44   Max: 186.01
Current: 33.55

-312.44
186.01
Net-margin (%) 23.61
RGEN's Net-margin (%) is ranked higher than
94% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. RGEN: 23.61 )
RGEN' s 10-Year Net-margin (%) Range
Min: -224.93   Max: 192.3
Current: 23.61

-224.93
192.3
ROE (%) 15.49
RGEN's ROE (%) is ranked higher than
93% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. RGEN: 15.49 )
RGEN' s 10-Year ROE (%) Range
Min: -239.58   Max: 57.88
Current: 15.49

-239.58
57.88
ROA (%) 13.56
RGEN's ROA (%) is ranked higher than
96% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. RGEN: 13.56 )
RGEN' s 10-Year ROA (%) Range
Min: -125   Max: 53.9
Current: 13.56

-125
53.9
ROC (Joel Greenblatt) (%) 88.19
RGEN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. RGEN: 88.19 )
RGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1560   Max: 1037.34
Current: 88.19

-1560
1037.34
Revenue Growth (%) 45.60
RGEN's Revenue Growth (%) is ranked higher than
96% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. RGEN: 45.60 )
RGEN' s 10-Year Revenue Growth (%) Range
Min: -49.7   Max: 45.6
Current: 45.6

-49.7
45.6
» RGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

RGEN Guru Trades in Q2 2013

Steven Cohen 10,398 sh (New)
Jim Simons 292,200 sh (-31.46%)
» More
Q3 2013

RGEN Guru Trades in Q3 2013

Jim Simons 349,100 sh (+19.47%)
Steven Cohen Sold Out
» More
Q4 2013

RGEN Guru Trades in Q4 2013

Joel Greenblatt 18,532 sh (New)
Jim Simons 563,400 sh (+61.39%)
» More
Q1 2014

RGEN Guru Trades in Q1 2014

Paul Tudor Jones 24,627 sh (New)
Joel Greenblatt 15,504 sh (-16.34%)
Jim Simons 465,993 sh (-17.29%)
» More
» Details

Insider Trades

Latest Guru Trades with RGEN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 New Buy0.01%$10 - $13.62 $ 22.2286%18532
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 40.20
RGEN's P/E(ttm) is ranked higher than
90% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 40.20 )
RGEN' s 10-Year P/E(ttm) Range
Min: 3.19   Max: 762.86
Current: 40.2

3.19
762.86
P/B 6.50
RGEN's P/B is ranked higher than
68% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. RGEN: 6.50 )
RGEN' s 10-Year P/B Range
Min: 1.42   Max: 7.59
Current: 6.5

1.42
7.59
P/S 10.66
RGEN's P/S is ranked higher than
77% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. RGEN: 10.66 )
RGEN' s 10-Year P/S Range
Min: 2.74   Max: 28.27
Current: 10.66

2.74
28.27
PFCF 28.00
RGEN's PFCF is ranked higher than
95% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 28.00 )
RGEN' s 10-Year PFCF Range
Min: 3.18   Max: 379
Current: 28

3.18
379
EV-to-EBIT 25.97
RGEN's EV-to-EBIT is ranked higher than
92% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 25.97 )
RGEN' s 10-Year EV-to-EBIT Range
Min: 1.7   Max: 2812.1
Current: 25.97

1.7
2812.1
Shiller P/E 108.70
RGEN's Shiller P/E is ranked higher than
93% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 108.70 )
RGEN' s 10-Year Shiller P/E Range
Min: 11.63   Max: 120.5
Current: 108.7

11.63
120.5
Current Ratio 12.45
RGEN's Current Ratio is ranked higher than
91% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. RGEN: 12.45 )
RGEN' s 10-Year Current Ratio Range
Min: 1.55   Max: 44.57
Current: 12.45

1.55
44.57
Quick Ratio 10.85
RGEN's Quick Ratio is ranked higher than
90% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. RGEN: 10.85 )
RGEN' s 10-Year Quick Ratio Range
Min: 1.4   Max: 43.88
Current: 10.85

1.4
43.88

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.80
RGEN's Price/Net Cash is ranked higher than
81% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. RGEN: 11.80 )
RGEN' s 10-Year Price/Net Cash Range
Min: 1.7   Max: 25.53
Current: 11.8

1.7
25.53
Price/Net Current Asset Value 10.20
RGEN's Price/Net Current Asset Value is ranked higher than
81% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. RGEN: 10.20 )
RGEN' s 10-Year Price/Net Current Asset Value Range
Min: 1.5   Max: 32.3
Current: 10.2

1.5
32.3
Price/Tangible Book 7.00
RGEN's Price/Tangible Book is ranked higher than
74% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. RGEN: 7.00 )
RGEN' s 10-Year Price/Tangible Book Range
Min: 0.94   Max: 14.59
Current: 7

0.94
14.59
Price/DCF (Projected) 3.60
RGEN's Price/DCF (Projected) is ranked higher than
93% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 3.60 )
RGEN' s 10-Year Price/DCF (Projected) Range
Min: 0.69   Max: 2.48
Current: 3.6

0.69
2.48
Price/Median PS Value 1.70
RGEN's Price/Median PS Value is ranked higher than
72% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. RGEN: 1.70 )
RGEN' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 11.49
Current: 1.7

0.18
11.49
Price/Graham Number 3.50
RGEN's Price/Graham Number is ranked higher than
90% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RGEN: 3.50 )
RGEN' s 10-Year Price/Graham Number Range
Min: 0.54   Max: 6.25
Current: 3.5

0.54
6.25
Earnings Yield (Greenblatt) 3.90
RGEN's Earnings Yield (Greenblatt) is ranked higher than
65% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. RGEN: 3.90 )
RGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 57.8
Current: 3.9

0.1
57.8
Forward Rate of Return (Yacktman) 0.95
RGEN's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. RGEN: 0.95 )
RGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.6   Max: 37.1
Current: 0.95

-3.6
37.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RGN.Germany
Repligen Corporation was incorporated in May 1981, under the laws of the State of Delaware. The Company is a life sciences company that develops, manufactures and markets consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies worldwide. It is also engaged in the manufacture of native and recombinant forms of Protein A, critical reagents used in bio manufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies several growth factor products used to increase cell culture productivity during the bio manufacturing process. In the burgeoning area of disposable bio manufacturing technologies, it has developed and currently markets a series of OPUS (Open-Platform, User-Specified) chromatography columns for use in clinical-scale manufacturing which are pre-packed, plug-and-play columns, uniquely flexible and customizable to customers' media and size requirements. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sell its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. It manufactures five forms of commercial scale Protein A including native Protein A for life sciences companies under long-term supply agreements which expire between 2016 and 2021. In December 2012, it out-licensed its SMA program, led by RG3039, to Pfizer Inc. The Company has developed RG1068, a synthetic human hormone for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and potentially other pancreatic diseases. It conducts manufacturing in Waltham and at its facility in Lund, Sweden. The Company currently has two therapeutic development programs available for outlicensing: RG1068, a diagnostic imaging agent for patients with pancreatic abnormalities; and RG2833, an early stage program for the treatment of Friedreich's Ataxia, a rare muscular disorder. It sells its bioprocessing products through direct sales force partners such as GE Healthcare, EMD Millipore, Sigma Aldrich and distributors in certain foreign markets.
» More Articles for RGEN

Headlines

Articles On GuruFocus.com
Repligen Corp. Reports Operating Results (10-Q) Feb 09 2011 
Repligen Corp. Reports Operating Results (10-Q) Nov 02 2010 
Repligen Corp. Reports Operating Results (10-Q) Aug 05 2010 
Repligen Corp. Reports Operating Results (10-Q) Feb 04 2010 
Repligen Corp. Reports Operating Results (10-Q) Nov 05 2009 
Repligen Reports First Quarter Fiscal Year 2010 Financial Results Aug 06 2009 
Repligen Corp. Reports Operating Results (10-Q) Feb 06 2009 

More From Other Websites
Repligen to Report Second Quarter 2014 Financial Results Jul 28 2014
Repligen to Report Second Quarter 2014 Financial Results Jul 28 2014
CFO Moves: Repligen Corp., Top Image Systems Ltd. Jul 15 2014
Repligen Hires Jon K. Snodgres as Chief Financial Officer Jul 15 2014
REPLIGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jul 15 2014
Repligen Hires Jon K. Snodgres as Chief Financial Officer Jul 15 2014
Repligen (RGEN) Shares March Higher, Can It Continue? Jun 27 2014
Repligen Appoints Nicolas M. Barthelemy to Board of Directors Jun 12 2014
REPLIGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jun 12 2014
Repligen Corp Conference Call to discuss the acquisition of Bioprocessing Business of Refine... Jun 03 2014
REPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Jun 03 2014
Repligen Acquires Bioprocessing Business of Refine Technology Jun 03 2014
Repligen to Present at Jefferies 2014 Global Healthcare Conference May 28 2014
Repligen management to meet with Jefferies May 19 2014
REPLIGEN CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... May 19 2014
REPLIGEN CORP Financials May 16 2014
REPLIGEN CORP Files SEC form 10-Q, Quarterly Report May 09 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide